EOK Marketing Says it will Discontinue All Challenged Claims for OmegaFlex Dietary Supplements, Following NAD Inquiry

New York, NY – Oct. 14, 2015 – EOK Marketing, LLC, which does business as Marine Essentials, has said it will discontinue all advertising claims for OmegaFlex Dietary Supplements challenged before the National Advertising Division by the Council for Responsible Nutrition.

NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.

CRN files challenges with NAD regarding advertising claims made for dietary supplements, in an effort to encourage manufacturers to provide substantiation for their advertising claims to an objective, third party for review and evaluation and to assure that claims being promoted to consumers are truthful, not misleading and are substantiated with credible scientific evidence.

In response to NAD’s inquiry, the advertiser advised NAD in writing that instead of submitting substantiating evidence, it had elected to permanently discontinue all of the challenged claims, including testimonials.

Claims at issue included:

• “Scientists have made an amazing breakthrough that can dramatically reduce your joint pain…And In As Little As Seven Days…”
  “With OmegaFlex you get the proven natural pain reducing properties of 5-Loxin… that is 60 times more powerful than normal boswellia.”
• “A 62% reduction in joint pain!”
• “Not only that, both groups also had a 60% reduction in stiffness…”

In reliance on the advertiser’s representation that the claims had been permanently discontinued, NAD did not review the claims on their merits.  The voluntarily discontinued claims will be treated, for compliance purposes, as though NAD recommended their discontinuance and the advertiser agreed to comply.

EOK Marketing, in its advertiser’s statement, said that in the spirit of self-regulation, it would comply with NAD’s recommendations.

Note: A recommendation by NAD to modify or discontinue a claim is not a finding of wrongdoing and an advertiser’s voluntary discontinuance or modification of claims should not be construed as an admission of impropriety. It is the policy of NAD not to endorse any company, product, or service. Decisions finding that advertising claims have been substantiated should not be construed as endorsements.